163 related articles for article (PubMed ID: 16133054)
1. Dialysate CA125 levels in children on continuous peritoneal dialysis.
Turhan P; Sever L; Caliskan S; Kasapcopur O; Sever A; Hacibekiroglu M; Arisoy N
Pediatr Nephrol; 2005 Nov; 20(11):1615-21. PubMed ID: 16133054
[TBL] [Abstract][Full Text] [Related]
2. Dialysate cancer antigen 125 levels in children treated with peritoneal dialysis.
Bouts AH; Groothoff JW; van Amstel SP; Zweers MM; Davin JC; Krediet RT
Adv Perit Dial; 2000; 16():328-31. PubMed ID: 11045322
[TBL] [Abstract][Full Text] [Related]
3. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
4. Dialysate CA125 levels after 5 years on continuous peritoneal dialysis.
Candan C; Turhan P; Sever L; Civilibal M; Canpolat N; Caliskan S; Kasapcopur O; Arisoy N
Pediatr Nephrol; 2011 May; 26(5):783-8. PubMed ID: 21279389
[TBL] [Abstract][Full Text] [Related]
5. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis.
Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
Adv Perit Dial; 1997; 13():17-22. PubMed ID: 9360644
[TBL] [Abstract][Full Text] [Related]
6. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters.
Lai KN; Lai KB; Szeto CC; Ho KK; Poon P; Lam CW; Leung JC
Am J Kidney Dis; 1997 May; 29(5):699-705. PubMed ID: 9159303
[TBL] [Abstract][Full Text] [Related]
7. Dialysate CA125 in stable CAPD patients: no relation with transport parameters.
Pannekeet MM; Koomen GC; Struijk DG; Krediet RT
Clin Nephrol; 1995 Oct; 44(4):248-54. PubMed ID: 8575125
[TBL] [Abstract][Full Text] [Related]
8. Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD.
Pannekeet MM; Zemel D; Koomen GC; Struijk DG; Krediet RT
Perit Dial Int; 1995; 15(6):217-25. PubMed ID: 7578497
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients.
Redahan L; Davenport A
J Nephrol; 2016 Jun; 29(3):427-434. PubMed ID: 26616639
[TBL] [Abstract][Full Text] [Related]
10. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.
Krediet RT
Perit Dial Int; 2001; 21(6):560-7. PubMed ID: 11783764
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients.
Passadakis P; Panagoutsos S; Thodis E; Tsivara I; Sopassi F; Kartali S; Vargemezis V
Adv Perit Dial; 1999; 15():40-4. PubMed ID: 10682070
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic role of peritoneal CA 125 in peritoneal dialysis patients presenting with acute peritonitis.
Panorchan K; Davenport A
BMC Nephrol; 2014 Sep; 15():149. PubMed ID: 25217152
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport.
Rodrigues A; Martins M; Santos MJ; Fonseca I; Oliveira JC; Cabrita A; Melo e Castro J; Krediet RT
Adv Perit Dial; 2004; 20():8-12. PubMed ID: 15384786
[TBL] [Abstract][Full Text] [Related]
14. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.
Visser CE; Brouwer-Steenbergen JJ; Betjes MG; Koomen GC; Beelen RH; Krediet RT
Nephrol Dial Transplant; 1995; 10(1):64-9. PubMed ID: 7724031
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal follow-up of CA125 in peritoneal effluent.
Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
Kidney Int; 1997 Mar; 51(3):888-93. PubMed ID: 9067926
[TBL] [Abstract][Full Text] [Related]
16. Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis.
Malik AR; Little MA; Henriksson M; Tam FW; Brown EA
J Nephrol; 2007; 20(3):340-9. PubMed ID: 17557268
[TBL] [Abstract][Full Text] [Related]
17. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
18. Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report.
Kim YL; Do J; Park SH; Cho K; Park J; Yoon K; Cho DK; Lee EG; Kim IS
Nephrology (Carlton); 2003 Oct; 8 Suppl():S28-32. PubMed ID: 15012688
[TBL] [Abstract][Full Text] [Related]
19. Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis.
Otsuka Y; Nakayama M; Ikeda M; Sherif AM; Yokoyama K; Yamamoto H; Kawaguchi Y
Clin Exp Nephrol; 2005 Dec; 9(4):315-319. PubMed ID: 16362159
[TBL] [Abstract][Full Text] [Related]
20. Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis.
Sanusi AA; Zweers MM; Weening JJ; de Waart DR; Struijk DG; Krediet RT
Perit Dial Int; 2001; 21(5):495-500. PubMed ID: 11757834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
